Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by JDavenporton Aug 23, 2021 9:54am
120 Views
Post# 33747837

RE:disease induction phase

RE:disease induction phaseFunniest post yet, pof. Induction phase? You don't even ask a question or make a statement. It's just another copy/paste job meant to create nervous agitation among investors. 

Let me assure the readers here that poof has no knowledge of these things and has no advice to offer to Bioasis chief medical officer Orfali, the scientific advisory board, nor to the CRO or pharmaceutical company scientists who did the work for Bioasis.

If this anonymous trader were to sit at the table with these scientists and physicians who designed and carried out the study, what would his input be, that Bioasis shouldn't be doing this work with IL-1Ra because a researcher, in appropriate desperation, is doing an anakinra study? Yeah, right! Laffer...!
 
Look, poof is going to be negative for now because he's a trader and Bioasis is obviously a pretty good buy at these prices. He'll flip to the positive side with the next press release. You can ignore that, as well.

jd
<< Previous
Bullboard Posts
Next >>